Progress in fibrinolysis

Research output: Contribution to journalArticlepeer-review


This review deals with aspects of fibrinolysis in which significant developments have taken place in the last few years. The structural changes of plasminogen during its activation are now identified precisely; the recent description of a thrombotic tendency in a kindred characterized by a defect of this protein emphasizes its important role in the homeostatic balance. Several activators of plasminogen are now identified; some of them, such as tissue and vascular activators, appear to have an important role in physiology and pathology. The recent characterizations of the α-antiplasmin and of antiactivators have widened our understanding of the inhibitors of fibrinolysis: a defect of the plasmin inhibitor seems to be associated with an hacmorrhagic tendency, whereas high antiactivator levels were encountered in thrombotic conditions. The clinical use of fibrinolytic agents appears to be promising in conditions such as recurrent deep vein thrombosis and in the post-phlebitic syndrome. Thrombolytic therapy with urokinase or streptokinase appears to have elective indications in patients with acute deep vein thrombosis and massive life-threatening pulmonary embolism.

Original languageEnglish
Pages (from-to)223-233
Number of pages11
JournalLa Ricerca in Clinica e in Laboratorio
Issue number3
Publication statusPublished - Jul 1979


  • Fibrinolysis
  • Fibrinolytic agents
  • Plasminogen
  • Thrombolysis
  • Thrombolytic agents

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Progress in fibrinolysis'. Together they form a unique fingerprint.

Cite this